Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II, Hunter syndrome). The deal covers mainland China, Macau, Taiwan and Hong Kong.

A Canbridge spokesperson said the company is responsible for regulatory development in China, but declined to disclose financial terms. Green Cross did not respond immediately to an inquiry...